JP2022538222A5 - - Google Patents
Info
- Publication number
- JP2022538222A5 JP2022538222A5 JP2021576274A JP2021576274A JP2022538222A5 JP 2022538222 A5 JP2022538222 A5 JP 2022538222A5 JP 2021576274 A JP2021576274 A JP 2021576274A JP 2021576274 A JP2021576274 A JP 2021576274A JP 2022538222 A5 JP2022538222 A5 JP 2022538222A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- acid sequence
- polypeptide according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025138827A JP2026000901A (ja) | 2019-06-26 | 2025-08-22 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866749P | 2019-06-26 | 2019-06-26 | |
| US62/866,749 | 2019-06-26 | ||
| US202063043486P | 2020-06-24 | 2020-06-24 | |
| US63/043,486 | 2020-06-24 | ||
| PCT/US2020/039682 WO2020264208A1 (en) | 2019-06-26 | 2020-06-25 | Egfr antigen binding fragments and compositions comprising same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025138827A Division JP2026000901A (ja) | 2019-06-26 | 2025-08-22 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538222A JP2022538222A (ja) | 2022-09-01 |
| JP2022538222A5 true JP2022538222A5 (https=) | 2023-07-04 |
| JP7847433B2 JP7847433B2 (ja) | 2026-04-17 |
Family
ID=74060335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576274A Active JP7847433B2 (ja) | 2019-06-26 | 2020-06-25 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
| JP2025138827A Pending JP2026000901A (ja) | 2019-06-26 | 2025-08-22 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025138827A Pending JP2026000901A (ja) | 2019-06-26 | 2025-08-22 | Ｅｇｆｒ抗原結合断片およびそれを含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230312729A1 (https=) |
| EP (1) | EP3990499A4 (https=) |
| JP (2) | JP7847433B2 (https=) |
| KR (1) | KR20220038356A (https=) |
| CN (1) | CN114729056A (https=) |
| AU (1) | AU2020303586A1 (https=) |
| CA (1) | CA3143522A1 (https=) |
| CL (1) | CL2021003435A1 (https=) |
| CO (1) | CO2022000404A2 (https=) |
| IL (1) | IL289100A (https=) |
| MX (1) | MX2021015882A (https=) |
| WO (1) | WO2020264208A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3976098A4 (en) | 2019-05-31 | 2023-01-18 | Zymeworks Inc. | METHOD OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT THAT TARGETS HER2 FOR THE TREATMENT OF BILAGE DUCT CANCER |
| MX2023013382A (es) | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. |
| KR20230041711A (ko) | 2020-06-25 | 2023-03-24 | 아뮤닉스 파마슈티컬스, 인크. | Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법 |
| US20240254241A1 (en) * | 2021-05-11 | 2024-08-01 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| KR20250133776A (ko) | 2023-02-10 | 2025-09-08 | 아뮤닉스 파마슈티컬스, 인크. | 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법 |
| CN121949565A (zh) | 2023-04-17 | 2026-05-01 | 阿穆尼克斯制药公司 | 靶向表皮生长因子受体的组合物及其制备和使用方法 |
| WO2025122957A1 (en) | 2023-12-08 | 2025-06-12 | Amunix Pharmaceuticals, Inc. | Protease activatable cytokines and methods for making and using the same |
| TW202547886A (zh) * | 2024-02-02 | 2025-12-16 | 美商黛安瑟斯醫療運營公司 | 用於治療ｃ１ｓ介導的疾病和病症的組成物、劑量和方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| RU2547595C2 (ru) * | 2008-08-18 | 2015-04-10 | Пфайзер Инк | Антитела против ccr2 |
| AU2014206217B2 (en) * | 2009-02-03 | 2015-09-17 | Amunix Pharmaceuticals, Inc. | Extended recombinant polypeptides and compositions comprising same |
| US20140155581A1 (en) * | 2011-07-06 | 2014-06-05 | Medimmune, Llc | Methods For Making Multimeric Polypeptides |
| WO2013059524A2 (en) * | 2011-10-18 | 2013-04-25 | Emory University | Antibodies directed against influenza |
| KR102442436B1 (ko) * | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| MY196448A (en) * | 2015-10-30 | 2023-04-12 | Genentech Inc | Anti-Htra1 Antibodies and Methods of use Thereof |
| SG10201912565QA (en) * | 2016-09-29 | 2020-02-27 | Amgen Inc | Low-viscosity antigen binding proteins and methods of making them |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| US20190336615A1 (en) * | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
-
2020
- 2020-06-25 MX MX2021015882A patent/MX2021015882A/es unknown
- 2020-06-25 CA CA3143522A patent/CA3143522A1/en active Pending
- 2020-06-25 WO PCT/US2020/039682 patent/WO2020264208A1/en not_active Ceased
- 2020-06-25 CN CN202080061211.XA patent/CN114729056A/zh active Pending
- 2020-06-25 US US17/621,978 patent/US20230312729A1/en active Pending
- 2020-06-25 EP EP20833213.0A patent/EP3990499A4/en active Pending
- 2020-06-25 KR KR1020227002556A patent/KR20220038356A/ko active Pending
- 2020-06-25 JP JP2021576274A patent/JP7847433B2/ja active Active
- 2020-06-25 AU AU2020303586A patent/AU2020303586A1/en not_active Abandoned
-
2021
- 2021-12-19 IL IL289100A patent/IL289100A/en unknown
- 2021-12-21 CL CL2021003435A patent/CL2021003435A1/es unknown
-
2022
- 2022-01-19 CO CONC2022/0000404A patent/CO2022000404A2/es unknown
-
2025
- 2025-08-22 JP JP2025138827A patent/JP2026000901A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538222A5 (https=) | ||
| JP7496091B2 (ja) | 合理的に設計された新規なタンパク質組成物 | |
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| CN114341186B (zh) | 双特异性抗LRRC15和CD3ε抗体 | |
| CN115605504A (zh) | 新型il-21前药及其使用方法 | |
| CN113166220A (zh) | 创新细胞因子前药 | |
| EP3087097B1 (en) | Multifunctional antibodies binding to egfr and met | |
| EP4047018B1 (en) | Tetravalent bispecific antibody against pd-1 and vegf, preparation method therefor, and use thereof | |
| TW201815820A (zh) | 雙特異性t細胞活化抗原結合分子 | |
| CN106573986A (zh) | 多特异性抗体 | |
| JP2023531494A5 (https=) | ||
| CN113968910A (zh) | 四价对称双特异性抗体 | |
| JP2026004299A5 (https=) | ||
| TW201934578A (zh) | 治療方法 | |
| EP4263584A1 (en) | Combination therapy for the treatment of cancer | |
| EP4559932A1 (en) | Multispecific antibody and use thereof | |
| KR20230003114A (ko) | TGFβR2 세포외 도메인 절단된 분자, TGFβR2 세포외 도메인 절단된 분자와 항-EGFR 항체의 융합 단백질, 및 융합 단백질의 항종양 용도 | |
| RU2022101309A (ru) | Антигенсвязывающие фрагменты для egfr и композиции, содержащие их | |
| US20220127362A1 (en) | Tetravalent bispecific antibody against pd-1/lag-3, preparation method therefor, and use thereof | |
| WO2025068449A1 (en) | Knob domain proteins | |
| JP2025540100A (ja) | 突然変異体ｉｌ－２ポリペプチドおよびｉｌ－２プロドラッグ | |
| JP2025511000A5 (https=) | ||
| HK40061166A (en) | Tetravalent bispecific antibody, preparation method therefor, and use thereof | |
| HK40097873A (zh) | 用於治疗癌症的组合疗法 | |
| HK40075930A (en) | TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN |